“While CGH microarrays are often used for research purposes, the considerable expertise and development required to commercialize these technologies has limited their use for diagnostic testing,” Joyce Schwartz, vice president and chief laboratory officer for Quest, said in a statement. She said the ClariSure assay “bridges the gap” between scientific research and clinical diagnostic testing and provides a faster diagnosis of developmental disorders.
Quest Diagnostics last week said that it is now offering a molecular diagnostic test that can detect chromosome abnormalities associated with 85 developmental disorders affecting children.
The ClariSure is a microarray-based comparative genomic hybridization test that will be used to diagnose patients with mental retardation and Down syndrome among other disorders. Quest said it expects to provide physicians with test results within five days of receiving specimens at one of its facilities.
The test is based on technologies developed by Quest’s Nichols Institute and other licensed methodologies.